Cyban news: Cyban celebrates International Women’s Day 2023 by announcing 50% female workforce
Melbourne | 8 March 2023
Cyban has achieved a rare and powerful milestone by reaching 50% female workforce across the company. Read more.
Media release: Cyban announces the appointment of The Honourable Jaala Pulford to its Board of Directors
MELBOURNE | 6 MARCH 2023
Australian medtech company Cyban has today announced the appointment of The Honourable Jaala Pulford to its Board of Directors.
Read the full release here.
Media release: Cyban ICP clinical trial
Melbourne |14 February 2023
In an Australian first clinical trial, Cyban demonstrates non-invasive brain monitor delivers equivalent results to invasive ICP monitoring to offer simple and safe alternative in treating critical brain injuries.
Read the full release here.
Cyban: Improving outcomes for brain injury patients
Melbourne | 12 October 2022
Founded by ICU physician Dr. Barry Dixon, Cyban is changing how head trauma is treated in the ICU, with its non-invasive device designed to detect and monitor brain hypoxia in patients who have experienced acute brain injury.
Read the full article written by i4 Connect here
Victorian Government’s Medtech Manufacturing Capability Program
Melbourne | 5 August 2022
We are pleased to announce that Cyban was awarded $100,000 of grant funding from the Victorian Government's Medtech Manufacturing Capability Program. We will use this funding to support the manufacture of additional prototypes for use in new clinical trials with Key Opinion Leaders in the US and the UK.
Read the full Government announcement here
Breaking news: Dr Barry Dixon sat down with Rhiannon Down at The Australian
Melbourne | 24 JUne 2022
Dr Barry Dixon sat down with Rhiannon Down at The Australian this week to talk about Cyban’s innovative brain pulse oximeter. He spoke about how he recognised that a major clinical challenge exists for patients with severe TBI due to current monitoring systems having significant limitations and failing to reliably detect and report brain hypoxia. These limitations mean that detection and treatment of tissue hypoxia is often delayed, resulting in a worse injury to the patient.
Our sensor developed aims to reduce or eliminate secondary injuries due to hypoxia by enabling early detection and intervention, for a better patient outcome.
Please see the interview with Barry here
Cyban successfully raises $5.25m in oversubscribed Series A round
Melbourne | 18 May 2022
Funding milestone positions company to prepare for launch of its lead product, a world-first, non-invasive Brain Pulse Monitor read more
Government funding supports cutting-edge manufacturers
Melbourne | 15 June 2021
Official announcement from the department for Industry, Science and Technology. Read the full Government announcement here.
Entrepreneurs' Programme - Accelerating Commercialisation Grant
Melbourne | 11 June 2021
Cyban, a Australian technology company focused on developing a novel, non-invasive continuous tissue oxygen monitor focusing on measuring cerebral (brain oxygen), announced today that it was awarded an $350,000 grant from Accelerating Commercialisation, under the Australian Government’s Entrepreneurs’ Programme.
Accelerating Commercialisation support will be used to help Cyban commercialise the novel Brain Pulse Oximeter and ultimately achieve broad adoption of this technology, initially in the United States where the traumatic brain injury market is estimated at $800m, in addition to the burden associated with 26m new cases of traumatic brain injury globally per annum.
This project is supported by the Australian Government Department of Industry, Science, Energy and Resources through the Accelerating Commercialisation Program.
BioMedTech Horizons (BMTH) Program
Melbourne | 1 april 2020
Cyban, a Australian technology company focused on developing a novel, non-invasive continuous tissue oxygen monitor focusing on measuring cerebral (brain oxygen), announced today that it was awarded an $960,000 grant from the BioMedTech Horizons (BMTH) Grant.
The aim of the project will develop and further demonstrate the efficacy of our brain pulse oximeter (BPOx) designed for non-invasive brain oxygen monitoring of acutely injured and critically ill patients in Emergency Departments (ED) and Intensive Care Units (ICU). Successful completion of this project will enable commercialisation in 2021.
Key activities in this project include:
Development of an advanced prototype
Undertaking clinical efficacy and health economic outcome research
Undertaking user needs analysis to inform product design
Engaging expert advice on intellectual property, regulatory approval, market access and business planning to support fundraising and commercialisation
With earlier detection and treatment of brain hypoxia, secondary brain injury may be prevented, and the risk of long-term disability and death reduced. We will target a global market segment estimated at US$800 million.
